Czasopismo
Tytuł artykułu
Warianty tytułu
Języki publikacji
Abstrakty
The aim of this study was to evaluate the serotype-specific pneumococcal status of children and adolescents with inflammatory bowel disease (IBD) who were naïve to pneumococcal vaccination before administering the 13-valent pneumococcal conjugate vaccine (PCV 13). This was an open, prospective study on children and adolescents aged 5–18 years who had IBD and were naïve to pneumococcal vaccination. A single dose of PCV 13 was administered to each patient. The geometric mean concentrations (GMCs) were measured for all 13 serotypes. A total of 122 subjects completed the study. Prevaccination GMCs ranged from 0.55 μg/ml (serotype 4) to 4.26 μg/ml (serotype 19A). Prior to the administration of PCV 13, high GMCs were detected in older children and adolescents who had IBD and were naïve to pneumococcal vaccination.
Słowa kluczowe
Wydawca
Czasopismo
Rocznik
Tom
Numer
Opis fizyczny
p.89-91,ref.
Twórcy
autor
- Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw, Poland
autor
- Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland
autor
- Department of Pediatrics, Gastroenterology and Nutrition, Polish-American Children’s Hospital, Jagiellonian University Medical College, Krakow, Poland
autor
- Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw, Poland
autor
- Department of Pediatric Gastroenterology, Hepatology and Nutrition, Medical University of Gdansk, Gdansk, Poland
autor
- Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw, Poland
- Department of Pediatrics, Medical University of Silesia, Katowice, Poland
autor
- Department of Pediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, Wroclaw, Poland
autor
- Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw, Poland
autor
- Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw, Poland
autor
- Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw, Poland
autor
- Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland
autor
- Department of Microbiology and Clinical Immunology, Children’s Memorial Health Institute, Warsaw, Poland
autor
- Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw, Poland
autor
- Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw, Poland
Bibliografia
- Bamford A., P. Kelleher, H. Lyall, M. Haston, M. Zancolli, D. Goldblatt and B. Kampmann. 2014. Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection. AIDS 28: 2033–2243.
- Centers for Disease Control and Prevention (CDC). 2013. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep. 62: 521–524.
- Concepcion N.F. and C.E. Frasch. 2001. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 8: 266–272.
- Frenck R.Jr., A. Thompson, S. Senders, L. Harris-Ford, M. Sperling, S. Patterson, C. Devlin, K.U. Jansen, W.C. Gruber, E.A. Emini and others. 2014. 13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 33: 183–189.
- Levine A., S. Koletzko, D. Turner, J.C. Escher, S. Cucchiara, L. de Ridder, K.L. Kolho, G. Veres, R.K. Russell, A. Paerregaard and others. 2014. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J. Pediatr. Gastroenterol. Nutr. 58: 795–806.
- Rubin L.G., M.J. Levin, P. Ljungman, E.G. Davies, R. Avery, M. Tomblyn, A. Bousvaros, S. Dhanireddy, L. Sung, H. Keyserling and others. 2014. Infectious diseases society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin. Infect. Dis. 58:309–318.
- Skoczyńska A., A. Kuch, E. Sadowy, I. Waśko, M. Markowska, P. Ronkiewicz, B. Matynia, A. Bojarska, K. Wasiak, A. Gołębiewska and others. 2015. Participants of a laboratory-based surveillance of community acquired invasive bacterial infections (BINet). Recent trends in epidemiology of invasive pneumococcal disease in Poland. Eur. J. Clin. Microbiol. Infect. Dis. 34: 779–787.
- World Health Organisation (WHO). 2005. Pneumococcal conjugate vaccines. Recommendations for the production and control of pneu-mococcal conjugate vaccines. WHO Tech. Rep. Ser. 927 (Annex 2): 64–98.
- Wernette C.M., C.E. Frasch, D. Madore, G. Carlone, D. Goldblatt, B. Plikaytis, W. Benjamin, S.A. Quataert, S. Hildreth, D.J. Sikkema and others. 2003. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin. Diagn. Lab. Immunol. 10: 514–519.
- Wysocki J., J. Brzostek, H. Szymański,B. Tetiurka, E. Toporowska- Kowalska, K. Wasowska-Królikowska, D.A. Sarkozy, P.C. Giardina, W.C. Gruber and others. 2015. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination. Vaccine 33: 1719–1725.
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.agro-57240884-e07d-44a6-848c-b43b31f7cc60